TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07786454: A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 1120 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07786454 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07786454 Rescue Dossier →